Stereotactic body radiotherapy in the treatment of advanced adenocarcinoma of the pancreas
American Journal of Clinical Oncology,  Clinical Article

Rwigema JC et al. – SBRT is feasible, with minimal grade ≥3 toxicity. The overall FFLP rate for all patients was 64.8%, comparable to rates with external beam radiotherapy. This shorter treatment course can be delivered without delay in adjuvant systemic therapy.


  • Reviewed outcomes of 71 patients treated with SBRT for pancreatic cancer between July 2004 and January 2009
  • 40 patients (56%) had locally unresectable disease, 11 patients (16%) had local recurrence following surgical resection, 8 patients (11%) had metastatic disease, and 12 patients (17%) received adjuvant SBRT for positive margins
  • Median dose 24 Gy (18–25 Gy), given in single-fraction SBRT (n = 67) or fractionated SBRT (n = 4)
  • Kaplan-Meyer survival analyses used to estimate freedom from local progression (FFLP) and OS rates

  • Median follow-up among surviving patients was 12.7 months (4–26 months)
  • The median tumor volume was 17 mL (5.1–249 mL)
  • Overall FFLP rates at 6 months/1 year 71.7%/48.5%
  • Among those with macroscopic disease, FFLP achieved in 77.3% of patients with tumor size <15 mL (n = 22), and 59.5% for ≥15 mL (n = 37) (P = 0.02)
  • FFLP achieved in 73% following 24 to 25 Gy, and 45% with 18 to 22 Gy (P = 0.004)
  • Median OS 10.3 months, with 6 month/1 year OS rates of 65.3%/41%, respectively
  • Grade 1–2 acute and late GI toxicity seen in 39.5% of patients
  • 3 patients experienced acute grade 3 toxicities

Please login or register to follow this author.
Are you sure you want to Unfollow this Author?
► Click here to access PubMed, Publisher and related articles...
<< Previous Article | Next Article >>

Your Unread Messages in Oncology

See All >> Messages include industry-sponsored communications and special communications from MDLinx

Most Popular Oncology Articles

Indexed Journals in Oncology: Journal of Clinical Oncology, Cancer Research, Annals Oncologymore

Register now to view all the MDLinx contents (FREE)!

  • Stay current on the latest literature, research and clinical news
  • Get special communications and offers from MDLinx and our sponsors
  • Receive invitations to paid market research
View Samples and Register

Connect with us, stay current.

Receive the latest mecial news
updates for free via email

Sign up!

Subscribe to our free RSS feeds:

Get the latest news in your specialty automatically added to your newsreader or your personal My Yahoo!, Google, My MSN or My AOL page. Learn More